News headlines about Invuity (NASDAQ:IVTY) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Invuity earned a news impact score of 0.17 on Accern’s scale. Accern also gave news articles about the medical instruments supplier an impact score of 45.6896697175018 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

IVTY has been the topic of several research reports. Northland Securities reaffirmed a “buy” rating and issued a $13.00 target price on shares of Invuity in a research report on Tuesday, May 16th. Zacks Investment Research lowered Invuity from a “hold” rating to a “sell” rating in a research report on Tuesday, June 13th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $10.00 target price on shares of Invuity in a research report on Wednesday, July 26th. William Blair reaffirmed a “buy” rating on shares of Invuity in a research report on Tuesday, May 23rd. Finally, ValuEngine raised Invuity from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $13.20.

Shares of Invuity (NASDAQ:IVTY) traded up 2.108% on Wednesday, hitting $8.475. The company had a trading volume of 14,723 shares. Invuity has a 12-month low of $4.50 and a 12-month high of $14.00. The company’s market cap is $144.50 million. The company has a 50 day moving average of $8.60 and a 200-day moving average of $8.06.

Invuity (NASDAQ:IVTY) last released its quarterly earnings data on Tuesday, July 25th. The medical instruments supplier reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.07). Invuity had a negative net margin of 114.61% and a negative return on equity of 140.69%. The business had revenue of $9.77 million during the quarter, compared to analyst estimates of $10.30 million. On average, analysts forecast that Invuity will post ($2.38) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Invuity (IVTY) Earns Media Impact Rating of 0.17” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/09/13/invuity-ivty-earns-media-impact-rating-of-0-17.html.

About Invuity

Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.

Insider Buying and Selling by Quarter for Invuity (NASDAQ:IVTY)

Receive News & Ratings for Invuity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity Inc. and related companies with MarketBeat.com's FREE daily email newsletter.